 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LCAR-AMDR / Legend Biotech
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 15, 2023
P1, N=4, Terminated, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
N=34 --> 4 | Trial completion date: Feb 2027 --> Sep 2023 | Recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Sep 2023; Both the sponsors and collaborator are considering terminating the study
- || LCAR-AMDR / Legend Biotech
Enrollment open: CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 31, 2023
P1, N=34, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
N=34 --> 4 | Trial completion date: Feb 2027 --> Sep 2023 | Recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Sep 2023; Both the sponsors and collaborator are considering terminating the study Not yet recruiting --> Recruiting
- || LCAR-AMDR / Legend Biotech
New P1 trial: CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2022
P1, N=34, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital